HOME >> MEDICINE >> NEWS
Improving informed consent for children in cancer treatment studies

Cleveland, Ohio: A study at six of the nation's leading children's hospitals has concluded that physicians should do a better job in communicating with parents before a child with cancer enrolls in a randomized clinical trial. "Our findings demonstrate that common strategies to explain the concept of randomization to patient families are not effective," explains Eric Kodish, MD, lead author of the study published in the Journal of the American Medical Association (JAMA, 1/28/04). Dr. Kodish is a pediatric oncologist and director of the Rainbow Center for Pediatric Ethics at Rainbow Babies & Children's Hospital in Cleveland, and professor of pediatrics at Case Western Reserve University School of Medicine.

The research also involved a Parent Advisory Group to help in the study design and analysis, with parents representing all the study sites, including: Rainbow; Children's Hospital Medical Center, Cincinnati, OH; Children's Hospital Los Angeles, CA; Children's Hospital of Philadelphia, PA; Children's National Medical Center in Washington, DC; and the MD Anderson Cancer Center in Houston, TX. The study was supported by the National Institutes of Health and the Children's Oncology Group, a network of pediatric medical centers.

As part of the study, researchers observed and audiotaped the informed consent conferences involving 137 families at the six medical centers from July 1, 1999 to December 31, 2001. The patients were children, all newly diagnosed with acute leukemia. Childhood cancer treatment commonly involves the option of participation in clinical trials, which have revolutionized pediatric cancer treatment and significantly improved outcomes. In fact, the authors note that: "Thousands of children with cancer have been enrolled in randomized clinical trials over the past 40 years. The cure of childhood leukemia, one of the great success stories of modern medicine, has been a direct result of these trials."

In every case confer
'"/>

Contact: Eileen Korey
Eileen.Korey@UHHS.com
216-844-3825
University Hospitals of Cleveland
27-Jan-2004


Page: 1 2 3 4

Related medicine news :

1. Improving access to healthy food has little effect on diet
2. NIH convenes State-of-the-Sceince Conference on Improving End-of-Life Care
3. Improving child survival in Kenya: Strengthening of district hospitals essential
4. Improving health care for children with special needs
5. Improving eye patient care with telemedicine standards
6. Improving the chances of successful organ transplants
7. Improving health for mothers and children in South Asia
8. Improving treatment of medulloblastoma, a common childhood brain tumor
9. Improving the quality of life for larynx cancer patients
10. Improving physical fitness, insulin sensitivity may help latino children at risk for type 2 diabetes
11. Improving accuracy of cross-cultural neuropsychological testing

Post Your Comments:
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Cached News: